http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+21/26796048.html si-local-file:///var/storage/secattach/20260721/26796048.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+21/26796048.html Tue, 21 Jul 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+21/26796048.html si-local-file:///var/storage/secattach/20260721/26796048.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+21/26796048.html Tue, 21 Jul 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+17/26331081.html si-local-file:///var/storage/secattach/20260417/26331081.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+17/26331081.html Fri, 17 Apr 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+17/26331081.html si-local-file:///var/storage/secattach/20260417/26331081.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+17/26331081.html Fri, 17 Apr 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+14++Filed+by%3A+AULT+MILTON+C+III/26325418.html si-local-file:///var/storage/secattach/20260416/26325418.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+14++Filed+by%3A+AULT+MILTON+C+III/26325418.html Thu, 16 Apr 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+14++Filed+by%3A+AULT+MILTON+C+III/26325418.html si-local-file:///var/storage/secattach/20260416/26325418.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Apr+14++Filed+by%3A+AULT+MILTON+C+III/26325418.html Thu, 16 Apr 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/Corporate+News/Alzamend+Neuro+reports+early+brain+study+data+for+AL001+compound/26278934.html <p>Alzamend Neuro Inc. (NASDAQ: ALZN) announced findings from a brain imaging study of its AL001 compound conducted at Massachusetts General Hospital. The study examined brain metabolite changes in six healthy subjects who received AL001 or lithium carbonate for two weeks.</p><p>The magnetic resonance spectroscopy analysis measured five brain metabolites across 18 brain regions. According to the company, AL001 reduced levels of myo-inositol in 17 of 18 brain regions compared to lithium carbonate's effect in 8 of 18 regions. Both compounds targeted myo-inositol reduction, which the company states is the intended mechanism for lithium-based treatments.</p><p>The study found that glutamate levels remained stable http://www.streetinsider.com/Corporate+News/Alzamend+Neuro+reports+early+brain+study+data+for+AL001+compound/26278934.html Tue, 07 Apr 2026 08:07:31 -0400 ALZN http://www.streetinsider.com/FDA/Alzamend+Neuro+reports+early+brain+study+data+for+AL001+compound/26278934.html <p>Alzamend Neuro Inc. (NASDAQ: ALZN) announced findings from a brain imaging study of its AL001 compound conducted at Massachusetts General Hospital. The study examined brain metabolite changes in six healthy subjects who received AL001 or lithium carbonate for two weeks.</p><p>The magnetic resonance spectroscopy analysis measured five brain metabolites across 18 brain regions. According to the company, AL001 reduced levels of myo-inositol in 17 of 18 brain regions compared to lithium carbonate's effect in 8 of 18 regions. Both compounds targeted myo-inositol reduction, which the company states is the intended mechanism for lithium-based treatments.</p><p>The study found that glutamate levels remained stable http://www.streetinsider.com/FDA/Alzamend+Neuro+reports+early+brain+study+data+for+AL001+compound/26278934.html Tue, 07 Apr 2026 08:07:31 -0400 ALZN http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/Press+Releases/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html <div class="xn-content"> <ul type="disc"><li><b><i>Potentially Distinct Brain Profile: </i></b>Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate</li><li><b><i>Expected Trends for Myo-Inositol Reduction</i></b>: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action</li><li><b><i>Potentially Preserved Glutamate Balance:</i></b> Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability</li></ul><p><span http://www.streetinsider.com/PRNewswire/Alzamend+Neuro+Reports+Encouraging+Pharmacodynamic+Data+from+Phase+II+Clinical+Trial+of+AL001+%26quot%3BLithium+in+Brain%26quot%3B+Study+in+a+Trial+Conducted+at+Massachusetts+General+Hospital/26280546.html Tue, 07 Apr 2026 08:00:00 -0400 A.07880129 A.35954321 A.40221050 ALZN O.20042365 O.20737027 O.21200813 O.50762730 http://www.streetinsider.com/Corporate+News/Alzamend+Neuro+reports+AL001+meets+bioequivalence+in+phase+II+trial/26220400.html <p>Alzamend Neuro Inc. (NASDAQ: ALZN) announced results from its phase II clinical trial showing that AL001, its lithium formulation, achieved bioequivalence with standard lithium carbonate while demonstrating higher lithium concentrations across all 26 measured brain regions.</p><p>The trial, conducted at Massachusetts General Hospital, found that AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels compared to standard lithium carbonate, meeting FDA bioequivalence requirements of 80% to 125%. The drug showed numerically higher lithium concentrations in every brain region measured, including a 7.8% increase in maximum whole-brain lithium exposure.</p><p>AL001 reached peak brain concentration in 6.7 hours versus http://www.streetinsider.com/Corporate+News/Alzamend+Neuro+reports+AL001+meets+bioequivalence+in+phase+II+trial/26220400.html Thu, 26 Mar 2026 08:02:07 -0400 ALZN